| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 别名 | PF-2545920 hydrochloride |
| Canonical SMILES | CN1N=C(C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C(C5=CC=NC=C5)=C1.Cl[H] |
| 分子式 | C25H21ClN4O |
| 分子量 | 428.91 |
| 溶解度 | DMSO: 25 mg/mL (58.29 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over the PDE. IC50: 0.37 nM (PDE10A)[1]. In the conditioned avoidance response assay (CAR), Mardepodect (PF-2545920) is active with an ED50 of 1 mg/kg. Administration of Mardepodect (PF-2545920) to mice causes a dose dependent increase in striatal cGMP. [1]. Wilson JM et al. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in D2 neurons than in D1 neurons in the neostriatum. Neuropharmacology. 2015 Dec;99:379-86. [2]. Verhoest PR et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009 Aug 27;52(16):5188-96. |
m.cnreagent.com